Skip to main content

Ankylosing Spondyloarthritis clinical trials at UCSF
1 in progress, 0 open to new patients

  • Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis

    Sorry, in progress, not accepting new patients

    Apremilast is a new, orally available, small molecule drug that specifically inhibits phosphodiesterase 4 (PDE4), an enzyme that modulates inflammatory cytokines. This clinical study tests whether apremilast can improve the signs and symptoms of ankylosing spondylitis.

    San Francisco, California and other locations